Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Non-Current Liabilities: 2012-2024

Historic Total Non-Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Non-Current Liabilities fell 2.70% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 2.70%. This contributed to the annual value of $2.8 billion for FY2024, which is 3.87% up from last year.
  • Per Ptc Therapeutics' latest filing, its Total Non-Current Liabilities stood at $2.8 billion for FY2024, which was up 3.87% from $2.7 billion recorded in FY2023.
  • Ptc Therapeutics' 5-year Total Non-Current Liabilities high stood at $2.8 billion for FY2024, and its period low was $1.5 billion during FY2020.
  • For the 3-year period, Ptc Therapeutics' Total Non-Current Liabilities averaged around $2.4 billion, with its median value being $2.7 billion (2023).
  • Data for Ptc Therapeutics' Total Non-Current Liabilities shows a peak YoY spiked of 120.74% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Total Non-Current Liabilities stood at $1.5 billion in 2020, then increased by 14.19% to $1.7 billion in 2021, then grew by 11.32% to $1.9 billion in 2022, then soared by 41.79% to $2.7 billion in 2023, then grew by 3.87% to $2.8 billion in 2024.